US Capitol Capsule: Clearing FDA's Generics Backlog Answer To Drug Price Controversy?
This article was originally published in Scrip
Executive Summary
With the recent "chatter" about the FDA's backlog of generic drug applications – some of it triggered by Capitol Hill's concerns over recent extreme price hikes of older medicines – regulators want to set the record straight: the agency is doing just fine in its reviews of those products, and actually is ahead of schedule, contrary to some reports and popular belief, officials told an exclusive small group of reporters on Oct. 16.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.